

AMENDMENTS TO THE CLAIMS

1. **(Previously presented)** Monoclonal antibody, for isolating and/or identifying at least one cell population which is selected from the group consisting of haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells, wherein the antibody binds to an epitope of CUB domain-containing protein 1(CDCP1) which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 or CUB4, which were deposited in the Deutsche Sammlung für Mikroorganismen und Zellkulturen [German collection of microorganisms and cell cultures] (DSMZ), in accordance with the Budapest treaty, under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on 14.08.2002, and DSM ACC2551, on 12.07.2002.

2. **(Previously presented)** Monoclonal antibody, which is produced by the hybridoma cell line CUB1, which is deposited in the DSMZ under the number DSM ACC2569.

3. **(Previously presented)** Monoclonal antibody, which is produced by the hybridoma cell line CUB2, which is deposited in the DSMZ under the number DSM ACC2566.

4. **(Previously presented)** Monoclonal antibody, which is produced by the hybridoma cell line CUB3, which is deposited in the DSMZ under the number DSM ACC2565.

5. **(Previously presented)** Monoclonal antibody, which is produced by the hybridoma cell line CUB4, which is deposited in the DSMZ under the number DSM ACC2551.

6. **(Cancelled)**

7. **(Original)** Hybridoma cell line, which produces an antibody according to Claim 2.

8. **(Original)** Hybridoma cell line, which produces an antibody according to Claim 3.

9. **(Original)** Hybridoma cell line, which produces an antibody according to Claim 4.

10. **(Original)** Hybridoma cell line, which produces an antibody according to Claim 5.

11.-17. **(Cancelled)**

18. **(Previously presented)** Pharmaceutical composition comprising at least one monoclonal antibody according to Claim 1.

19. **(Previously presented)** Pharmaceutical composition comprising at least one monoclonal antibody according to Claim 2.

20. **(Previously presented)** Pharmaceutical composition comprising at least one monoclonal antibody according to Claim 3.

21. **(Previously presented)** Pharmaceutical composition comprising at least one monoclonal antibody according to Claim 4.

22. **(Previously presented)** Pharmaceutical composition comprising at least one monoclonal antibody according to Claim 5.

23. **(Previously presented)** Kit, comprising at least one monoclonal antibody according to Claim 1.

24. **(Previously presented)** Kit, comprising at least one monoclonal antibody according to Claim 2.

25. **(Previously presented)** Kit, comprising at least one monoclonal antibody according to Claim 3.

26. **(Previously presented)** Kit, comprising at least one monoclonal antibody according to Claim 4.

27. **(Previously presented)** Kit, comprising at least one monoclonal antibody according to Claim 5.

28. **(Currently amended)** A fragment of the monoclonal antibody of Claim 2, wherein said fragment is selected from the group consisting of F_{ab} , $F_{(ab)2'}$, F_v and complementary-determining regions (CDRs), and wherein said fragment retains antigen-binding specificity of said antibody.

29. **(Currently amended)** A fragment of the monoclonal antibody of Claim 3, wherein said fragment is selected from the group consisting of F_{ab} , $F_{(ab)2'}$, F_v and complementary-determining regions (CDRs), and wherein said fragment retains antigen-binding specificity of said antibody.

30. **(Currently amended)** A fragment of the monoclonal antibody of Claim 4, wherein said fragment is selected from the group consisting of F_{ab} , $F_{(ab)2'}$, F_v and complementary-determining regions (CDRs), and wherein said fragment retains antigen-binding specificity of said antibody.

31. **(Currently amended)** A fragment of the monoclonal antibody of Claim 5, wherein said fragment is selected from the group consisting of F_{ab} , $F_{(ab)2'}$, F_v and complementary-determining regions (CDRs), and wherein said fragment retains antigen-binding specificity of said antibody.

32. **(Previously presented)** A pharmaceutical composition comprising the fragment of Claim 28.

33. **(Previously presented)** A pharmaceutical composition comprising the fragment of Claim 29.

34. **(Previously presented)** A pharmaceutical composition comprising the fragment of Claim 30.

35. **(Previously presented)** A pharmaceutical composition comprising the fragment of Claim 31.